UK ITP Treatment Update: Quentin Hill on Generic Eltrombopag Access and Guidance
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, has shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag.
Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licensed treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar, and greater use of generic eltrombopag will result in a substantial, multi-million-pound cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP.
However, patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
You can find more information here.
Find more posts on Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity